Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Toon andere (1) versies

BACKGROUND: Immunomodulatory drugs have been shown to be only modestly effective in clinically definite relapsing remitting multiple sclerosis (RRMS). It has been hypothesized that their efficacy could be higher if used at the first appearance of symptoms, that is in the clinically isolated syndrom...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Clerico, M, Faggiano, F, Palace, J, Rice, G, Tintorè, M, Durelli, L
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2008

Gelijkaardige items

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
door: Clerico, M, et al.
Gepubliceerd in: (2008)

Treatment for delaying conversion of the first demyelinating event to multiple sclerosis: a Cochrane review on use of recombinant interferon beta or glatiramer acetate
door: Clerico, M, et al.
Gepubliceerd in: (2005)

Recombinant interferon-beta efficacy in preventing conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane meta-analysis
door: Clerico, M, et al.
Gepubliceerd in: (2006)

Early treatment to prevent conversion of clinically isolated syndrome to clinically defined multiple sclerosis: a Cochrane metanalysis
door: Clerico, M, et al.
Gepubliceerd in: (2008)

Conversion from clinically isolated syndromes to multiple sclerosis: how could we prevent it? A Cochrane review of published trials
door: Clerico, M, et al.
Gepubliceerd in: (2007)

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort
door: Valéria Coelho Santa Rita Pereira, et al.
Gepubliceerd in: (2012-10-01)

Immunomodulatory treatments for preventing conversion from clinically isolated syndromes to multiple sclerosis: a Cochrane review on their efficacy
door: Clerico, M, et al.
Gepubliceerd in: (2007)

Prevention of conversion of clinically isolated syndromes to clinically defined multiple sclerosis. Evidence from a Cochrane meta-analysis
door: Clerico, M, et al.
Gepubliceerd in: (2008)

Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation
door: GJ Melendez-Torres, et al.
Gepubliceerd in: (2017-09-01)

A comparative study of melatonin and immunomodulatory therapy with interferon beta and glatiramer acetate in a mouse model of multiple sclerosis
door: E.J. Ramos González, et al.
Gepubliceerd in: (2021-05-01)

To differentiate the indication to treat the clinically isolated syndrome on the bases of different clinical onsets. The subgroup analyses from a Cochrane meta-analysis
door: Clerico, M, et al.
Gepubliceerd in: (2009)

A Cochrane review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to multiple sclerosis
door: Clerico, M, et al.
Gepubliceerd in: (2006)

New features of glatiramer acetate for the treatment of remitting multiple sclerosis
door: N. Y. Lasch
Gepubliceerd in: (2015-12-01)

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
door: Katarzyna Kapica-Topczewska, et al.
Gepubliceerd in: (2019-01-01)

Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages
door: G. J. Melendez-Torres, et al.
Gepubliceerd in: (2018-10-01)

Pharmacoeconomic assessment of the effectiveness of glatiramer acetate (Copaxone®) in patients with multiple sclerosis
door: G. Ya. Shvarts
Gepubliceerd in: (2005-06-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
door: Özlem Taşkapılıoğlu, et al.
Gepubliceerd in: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
door: Özlem Taşkapılıoğlu, et al.
Gepubliceerd in: (2012-03-01)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
door: Oscar Fernández
Gepubliceerd in: (2012-08-01)

Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
door: Massimiliano Mirabella, et al.
Gepubliceerd in: (2022-04-01)

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
door: Mikhail Melnikov, et al.
Gepubliceerd in: (2020-01-01)

Nicolau syndrome following glatiramer acetate for multiple sclerosis: Case and review of reports
door: Methma Udawatta, et al.
Gepubliceerd in: (2024-04-01)

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis
door: Aaron Boster, et al.
Gepubliceerd in: (2011-09-01)

Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis
door: P Tappenden, et al.
Gepubliceerd in: (2004-06-01)

Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?
door: Anna Gil-Sánchez, et al.
Gepubliceerd in: (2024-04-01)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
door: Arielle Kasindi, et al.
Gepubliceerd in: (2022-05-01)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
door: Arthur Komlosh, et al.
Gepubliceerd in: (2019-07-01)

Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis
door: Genaro Gabriel Ortíz, et al.
Gepubliceerd in: (2022-06-01)

Interleukins (IL-23 and IL-27) serum levels: Relationships with gene polymorphisms and disease patterns in multiple sclerosis patients under treatment with interferon and glatiramer acetate
door: Ioana S. Barac, et al.
Gepubliceerd in: (2023-06-01)

GLATIRAMER ACETATE IS A FIRST-LINE DUAL-ACTION DRUG FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
door: T. E. Shmidt
Gepubliceerd in: (2016-12-01)

MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate
door: Ignacio Casanova, et al.
Gepubliceerd in: (2023-10-01)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
door: Justin M. Honce, et al.
Gepubliceerd in: (2020-09-01)

Embolia Cutis Medicamentosa after Subcutaneous Injection with Glatiramer Acetate
door: Lyubomira Vlahova, et al.
Gepubliceerd in: (2021-02-01)

Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers
door: Oliver Neuhaus, et al.
Gepubliceerd in: (2021-03-01)

microRNA Expression and Its Association With Disability and Brain Atrophy in Multiple Sclerosis Patients Treated With Glatiramer Acetate
door: María I. Dominguez-Mozo, et al.
Gepubliceerd in: (2022-06-01)

Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report
door: Afsaneh Shirani, et al.
Gepubliceerd in: (2021-11-01)

Prophylactic Glatiramer Acetate Treatment Positively Attenuates Spontaneous Opticospinal Encephalomyelitis
door: Ümmügülsüm Koc, et al.
Gepubliceerd in: (2023-02-01)

Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
door: Fadi Towfic, et al.
Gepubliceerd in: (2014-01-01)

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
door: Oreja-Guevara Celia, et al.
Gepubliceerd in: (2012-09-01)

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
door: Apfel Rainer, et al.
Gepubliceerd in: (2008-09-01)